Price
Target price
€6.99
€6.99
15.920%
0.96
15.920%
€10.19
19.01.26 / Frankfurt
WKN: A2AFXS / Symbol: CRVS / Name: Corvus / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Corvus Pharmaceuticals Inc Stock
A very strong showing by Corvus Pharmaceuticals Inc today, with an increase of €0.96 (15.920%) compared to yesterday's price.
We see a rather positive sentiment for Corvus Pharmaceuticals Inc with 9 Buy predictions and 2 Sell predictions.
With a target price of 10 € there is a positive potential of 43.06% for Corvus Pharmaceuticals Inc compared to the current price of 6.99 €.
Our community identified positive and negative aspects for Corvus Pharmaceuticals Inc stock for the coming years. 0 users see the criterium "Brand" as a plus for the Corvus Pharmaceuticals Inc stock. On the other hand our users think that "Brand" could be a problem in the future.
Pros and Cons of Corvus Pharmaceuticals Inc in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Corvus Pharmaceuticals Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Corvus Pharmaceuticals Inc | 15.920% | 24.377% | 9.561% | 45.473% | 12.924% | 807.085% | 128.431% |
| Ardelyx Inc. | 14.210% | 9.666% | 36.225% | 36.030% | 34.894% | 129.432% | 17.691% |
| Evolus Inc | -0.930% | -11.203% | -27.458% | -56.103% | -21.468% | -54.709% | -8.155% |
| Champions Oncology Inc | - | 7.143% | 2.564% | -34.783% | 3.448% | 50.000% | -35.484% |
Comments
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Show more
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Show more
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Show more
Ratings data for CRVS provided by MarketBeat
News
Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data
Corvus Pharmaceuticals (NASDAQ:CRVS), an immuno-oncology and dermatology drug developer, closed Tuesday at $21.41, up 165.96%. The stock moved higher after Phase 1 soquelitinib data in atopic
Corvus (CRVS) Q2 Loss Beats Estimates
Corvus Pharmaceuticals (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on developing immunology and oncology therapies, released its earnings results for Q2 2025 on August 7, 2025